MOGAD is an immune-system condition that causes attacks of inflammation in the brain, spinal cord, and especially the nerves behind the eyes. It was long mistaken for multiple sclerosis, but it is now recognised as its own disease with its own blood test and its own treatment choices.1University of Colorado Anschutz Medical Campus. New Diagnostic Criteria for MOGAD Distinguishes the Disease from MS and NMOSD Unlike MS, it often looks dramatic at first and then heals surprisingly well, so the bigger long-term question is usually whether attacks return rather than whether things steadily worsen.
What Happens in the Body With MOGAD
Nerves in the brain, spinal cord, and optic nerves are wrapped in myelin, an insulating coating that speeds up electrical signals. On the outermost layer of that coating sits a protein known as MOG. In MOGAD the immune system makes an antibody against it, called the MOG antibody (MOG-IgG), which is the name you may see on a lab report.2Practical Neurology. The Evolution of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease The antibody alone doesn’t do the damage. It boosts an attack led by immune T cells and helps mark the coating for destruction.3PubMed Central. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease
Around 40% of people with NMOSD-like symptoms who lack the NMOSD antibody turn out to have the MOG antibody.4University of Colorado Anschutz Medical Campus. New Diagnostic Criteria for MOGAD Distinguishes the Disease from MS and NMOSD That finding helped establish MOGAD as a separate condition, with its own imaging, test, and course.5PubMed. NMOSD and MOGAD: an evolving disease spectrum MS and NMOSD mostly affect women, but MOGAD affects men and women about equally. It occurs in children and adults and has no clear link to ethnicity.6University of Colorado Anschutz Medical Campus. New Diagnostic Criteria for MOGAD Distinguishes the Disease from MS and NMOSD
Hearing “it’s not MS” matters in practice. MS medicines appear not to help MOGAD, so the label changes treatment. If you were first told you had MS, doctors may revise that diagnosis once the antibody test comes back, and that is not a mistake on your part.
Nobody knows exactly why the immune system turns on MOG. It isn’t inherited in a simple way, and nothing you did caused it. Infections, and rarely vaccines, have been noted before onset.
Symptoms of MOGAD Attacks
The commonest first attack is optic neuritis, inflammation of the nerve linking eye to brain. It is how the disease starts in 60% of adults and 34% of children.7PubMed. MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally Nearly 9 in 10 of these attacks begin with eye pain or a headache behind the eye.8PubMed Central. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis The pain typically starts about 3 days before vision fades, and vision usually keeps worsening for about 4 days before it bottoms out.9PubMed Central. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis Both eyes are often affected, and doctors often see a swollen optic disc when they look into the eye.10PubMed Central. Clinical and neuroimaging findings in MOGAD–MRI and OCT11PubMed. MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally
Pink eye brings redness and discharge, not pain on moving the eye with fading vision, so it is a different problem. In optic nerve inflammation, colours, especially red, may look washed out, and the loss is often a central blur or dimness rather than floaters.
Transverse myelitis, inflammation across the spinal cord, can bring weakness, numbness, and bladder or bowel problems. The lowest tip of the cord is often involved in MOGAD, which helps explain bladder, bowel, and sexual symptoms.12PubMed Central. Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease These attacks usually build over hours to days rather than in a single instant. Numbness, tingling, or a band-like tightness around the trunk may come first, followed by heaviness or weakness in the legs. Many people notice bladder changes early, such as urgency, hesitation, or not feeling that the bladder is full.
ADEM, widespread brain inflammation, can cause confusion, drowsiness, and several symptoms at once, mostly in children.13Exploration of Neuroprotective Therapy. The diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in children A newer recognised form, cortical encephalitis, causes seizures, usually in adults.14Neurology. Cortical Seizures and MOG-IgG Positivity: A Multidisciplinary Case of FLAMES in MOGAD
Age shapes the picture. Children more often have several symptoms at once, such as limb weakness in 60% and confusion in 30%.15PubMed. Clinical and radiological characteristics of MOG antibody-associated disease (MOGAD): a comparative study between pediatric and adult cohorts Adults mostly have optic nerve inflammation, in about 62%.16PubMed. Clinical and radiological characteristics of MOG antibody-associated disease (MOGAD): a comparative study between pediatric and adult cohorts Very young children can show a rarer pattern.17Exploration of Neuroprotective Therapy. The diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in children
Eye pain on movement followed by blurred or dim vision needs same-day eye or emergency care. New leg weakness, numbness rising up the body, or trouble passing urine is an emergency. So is a first seizure or sudden confusion in a child. Fast treatment helps vision recover, so don’t wait to see if it passes.
How MOGAD Is Diagnosed
Diagnosis rests on a blood test for the MOG antibody plus a typical attack. The test is a cell-based assay, in which your blood is mixed with cells displaying MOG, and your report may name this method.18PubMed. MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment The live-cell version is the most accurate, while the fixed-cell commercial kit misses more cases. In one comparison the fixed test missed about 3 in 10 people the live test confirmed.19PubMed. MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment False positives are uncommon across labs, though a low positive result is more likely to be a false alarm.20PubMed Central. A multicenter comparison of MOG-IgG cell-based assays21PubMed Central. Live-Cell-Based Assay Outperforms Fixed Assay in MOGAD Diagnosis: A Retrospective Validation Against the 2023 International Criteria
It is a simple blood draw with no special preparation, though results can take days to weeks if the sample goes to a specialist lab. The antibody test doesn’t measure how severe an attack is or how much damage has occurred. A positive result isn’t a diagnosis on its own, because doctors also need an attack that fits the MOGAD pattern. A negative result doesn’t always close the question when the story and scans strongly fit, since some people turn positive only on repeat testing. Testing during an attack, before treatment, gives the clearest result.
Reports may give a titer, the antibody level measured by diluting the blood.22PubMed. MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment Under 2023 criteria, a low titer needs extra supporting features, such as typical MRI findings.23PubMed. MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment
It helps to ask whether a live or fixed cell-based assay was used, and to ask for the antibody level if the report says only “positive.” If the result is negative but suspicion is strong, ask about retesting at a specialist lab.
MRI adds clues. In the eye, the inflammation is often long and at the front of the optic nerve, frequently on both sides, with the nerve sheath lit up.24PubMed Central. Clinical and neuroimaging findings in MOGAD–MRI and OCT25PubMed Central. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis Spinal lesions are often long, spanning 3 or more vertebrae, and may form an “H” shape in the grey matter.26PubMed Central. Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease The first spinal MRI is normal in up to 1 in 10 people, so a repeat within days may be needed.27PubMed Central. Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease Spinal fluid usually lacks the oligoclonal bands typical of MS; in MOGAD they appear in only about 1 in 10 samples.28PubMed Central. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients
MS is often suspected first because optic neuritis and myelitis occur in both. MS brain scans usually show many small white matter spots, while MOGAD often shows few. MOGAD lesions also often fade on later scans, unlike MS.
Treating a MOGAD Attack
Attacks are usually treated with high-dose intravenous steroids,29PubMed. The Treatment of Myelin Oligodendrocyte Glycoprotein Antibody Disease: A State-of-the-Art Review which speed up vision recovery.30PubMed. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease A longer oral steroid taper afterward may prevent a quick rebound attack.31PubMed. The Treatment of Myelin Oligodendrocyte Glycoprotein Antibody Disease: A State-of-the-Art Review If steroids aren’t enough, plasma exchange, which filters antibodies from the blood, is added.32PubMed Central. Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
The IV steroids are usually given daily for several days in hospital or a day unit. Side effects can include poor sleep, mood changes, and high blood sugar. Stopping a taper early can trigger a rebound, so follow the schedule, and ask your doctor how long yours will last.
Recovery is often good. In attacks treated with plasma exchange, typical vision improved from 20/400 to 20/20.33PubMed Central. Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease In one group, 22 of 23 people with optic nerve inflammation almost fully regained vision.34PubMed. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease Rarely, very extensive damage reaching the crossing point behind the eyes leaves lasting severe vision loss.35PubMed. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease Spinal lesions fully clear on MRI in 62 to 79% of cases.36PubMed Central. Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
Vision often improves over weeks, with colour lagging behind sharpness. Bladder and leg symptoms can take longer, and some symptoms, such as fatigue, may linger after scans look normal.
In children, adding IVIG or plasma exchange during the first attack was linked to fewer relapses.37PubMed Central. Acute Attack Treatment Escalation and Subsequent Relapse Risk in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Early relapse fell from 28% with steroids alone to 4% with added treatment.38PubMed Central. Acute Attack Treatment Escalation and Subsequent Relapse Risk in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Will MOGAD Come Back
About 20 to 30% of people have another attack within two years, and 40 to 60% within five.39PubMed Central. Highly Aggressive Relapsing Course of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease Requiring Intensive Care Unit Treatment and Quadruple Immunotherapy Most repeat attacks are optic nerve inflammation, around 60 to 70%.40PubMed Central. Highly Aggressive Relapsing Course of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease Requiring Intensive Care Unit Treatment and Quadruple Immunotherapy
In some groups, children and males had a higher relapse risk.41PubMed. Clinical characteristics of pediatric and adult myelin oligodendrocyte antibody-associated disease (MOGAD): A single-center study in the Northeast A high antibody level of 1:32 or more was more common in people who relapsed,42PubMed Central. The nomogram model predicts relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease: a single-center study so some doctors recheck antibody levels as one clue among several, not a reliable predictor on its own. In one small group, about a third had lasting problems, mainly with vision.43PubMed Central. Clinical characteristics and long-term follow-up outcomes of myelin oligodendrocyte glycoprotein antibody-associated disease in Han Chinese participants
Doctors can’t yet predict reliably who will relapse. Knowing the warning signs means a new attack can be treated fast, and it helps to keep a record of each attack and its treatment.
Preventing Future Attacks
Timing matters. Adults who started preventive treatment after their first attack had about a quarter the odds of a new attack. Their relapse risk was 11% at two years versus 41% without.44PubMed. Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 Study
Monthly IVIG showed the fewest relapses in one large study.45PubMed Central. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder Rituximab, azathioprine, and mycophenolate also reduce relapses.46PubMed Central. Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody–associated disease: a systematic review and meta-analysis MS drugs don’t protect: all 9 people on them had breakthrough attacks.47PubMed Central. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder If you were on an MS drug before your MOGAD diagnosis, ask about switching.
After a single attack, some doctors wait, since many people never relapse. Others start early for severe attacks or high antibody levels. The choice weighs the infection risk of immune suppression against the risk of another attack, so ask about your own risk factors.
Day to day, IVIG involves infusions every few weeks, while rituximab is an infusion every few months. Regular blood tests check for side effects, and vaccines should be discussed before starting.
Newer options are arriving. Satralizumab cut relapse risk by 68% versus placebo in the first successful MOGAD trial.48PubMed Central. Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): acute attacks, relapse prevention, and symptomatic care Rozanolixizumab is in a phase 3 trial for relapsing MOGAD,49PubMed Central. Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): acute attacks, relapse prevention, and symptomatic care and tocilizumab is also under study.50PubMed. Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape
MOGAD in Children and at School
After onset, about 4 in 10 children received an educational intervention, up from under 1 in 10 before.51PubMed Central. Cognitive and academic outcomes in children with myelin oligodendrocyte glycoprotein antibody‐associated disease About 1 in 5 needed a learning support assistant at last follow-up.52PubMed Central. Cognitive and academic outcomes in children with myelin oligodendrocyte glycoprotein antibody‐associated disease Thinking problems are nonetheless less common than in children with a similar illness without the antibody,53PubMed Central. Impact of autoantibodies against myelin oligodendrocyte glycoprotein in paediatric acquired demyelinating disease: Intellectual functioning and academic performance though children with relapsing MOGAD may process information slightly more slowly.54PubMed. Cognitive function in pediatric-onset relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
If schoolwork changes, ask for a cognitive assessment. Vision changes may call for different seating or larger print, and fatigue after steroids may mean a phased return. Sharing a plan with teachers on warning signs helps them act quickly.
MOGAD and Pregnancy
Across several groups, almost no attacks occurred during pregnancy.55PubMed. Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease Relapse risk returns after birth, with a few attacks in the first 3 months.56PubMed. Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease In one Asian group, three-quarters of women with one prior attack had a postpartum relapse, though most recovered well. Most babies were born healthy.57PubMed. Outcomes and disease activity during and after pregnancy in Asian women with MOGAD
Discuss timing with your neurologist before trying to conceive. Some preventive drugs must be stopped or switched beforehand, and it is worth asking about restarting treatment soon after birth. Eye pain or weakness after the baby arrives should be reported promptly.